ciglitazone has been researched along with Granulocytic Leukemia in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mashayekhi, S | 1 |
| Yousefi, B | 1 |
| Tohidi, E | 1 |
| Darband, SG | 1 |
| Mirza-Aghazadeh-Attari, M | 1 |
| Sadighparvar, S | 1 |
| Kaviani, M | 1 |
| Shafiei-Irannejad, V | 1 |
| Kafil, HS | 1 |
| Karimian, A | 1 |
| Jadidi-Niaragh, F | 1 |
| Majidinia, M | 1 |
1 other study available for ciglitazone and Granulocytic Leukemia
| Article | Year |
|---|---|
Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ce | 2019 |